Developer docs
API playgroundTry for free, no card

Search company profiles

CardioMech

Full company profile

uuid000255l

Namestring
CardioMech
Legal namestring
CardioMech AS
Websiteurl
cardiomech.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CardioMech AS is a privately held Norwegian medical device company developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter platform designed to treat degenerative mitral regurgitation (DMR) without open-heart surgery. The system deploys artificial chord(s) through a transfemoral, transseptal catheter to replace broken or elongated native chordae tendineae, restoring native valve anatomy on a beating heart under echocardiographic guidance. Procedures are designed to be simple and potentially sub-hour for straightforward cases, with the ability to deploy up to two chords for more complex anatomy, and the small implant size is intended to preserve future surgical or transcatheter therapy options. The device is positioned as a potential first-line transcatheter therapy for both surgery-eligible and surgery-ineligible DMR patients, targeting the same disease space as the $6B-plus TAVR market but for the mitral valve.

The company is headquartered in Trondheim, Norway, with US operations in Fridley, Minnesota to support clinical trials and regulatory engagement in the US market. CardioMech MVRS is investigational only and not approved for sale in any geography; an Early Feasibility Study is registered on clinicaltrials.gov. Leadership includes co-founders Jacob Bergsland (CMO) and Nikolai Hiorth (CTO), CEO/President Rick Nehm, and Chairman Ramin Mousavi, the former CEO of CathWorks (acquired by Medtronic for $585M in April 2026), who brings Edwards Lifesciences and Baxter experience.

The business model is a future medical-device hardware-sale model: revenue will ultimately be generated through sale of the artificial-chord implant and delivery system to hospitals and cardiac centers performing transcatheter mitral valve repair, supplemented by clinical training and support services. Pricing is not publicly disclosed because no commercial sales exist today. The company has raised approximately $84M cumulatively across eight disclosed rounds between 2019 and April 2025, with recent rounds led or backed by Hadean Ventures, Investinor, Aerion Partners, and an undisclosed strategic investor; all US capital raises have been registered via SEC Form D filings.

Short descriptiontext

CardioMech is a Norwegian medical device company developing the CardioMech MVRS, a transcatheter mitral valve repair system using artificial chordal replacement to treat degenerative mitral regurgitation as a less-invasive alternative to open-heart surgery. It targets interventional cardiologists, cardiac surgeons, and DMR patients in Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTrondheim, Norway
HQ citystring
Trondheim
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
structural heart devices, mitral valve repair, transcatheter cardiac devices, artificial chord implants, degenerative mitral regurgitation therapy
Industry1 code
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Structural Heart Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

As a medical device company developing an implantable device for transcatheter mitral valve repair, CardioMech will generate revenue through the sale of its artificial chord implants and associated delivery systems to hospitals and cardiac centers performing the procedures.

cardiomech.com
2Clinical Training and Support
TypeProfessional Services
Description

Potential revenue from training, support, and clinical consultation services for hospitals and cardiac centers adopting the CardioMech MVRS platform.

cardiomech.com
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CardioMech is developing the CardioMech MVRS, a transcatheter mitral valve repair platform that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart. The system is intended as a less-invasive alternative to open-heart surgery for patients with degenerative mitral regurgitation, including those considered surgically ineligible. The device is for investigational use only and is not yet available for sale.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Potential to reduce the need for open-heart surgery in degenerative mitral regurgitation patients
+2 more records
Product overview1 text field

CardioMech is developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter mitral valve repair platform. The system uses artificial chords designed to reduce or eliminate mitral regurgitation and restore native anatomy. It is a catheter-based therapy intended as an alternative to open-heart surgery and potentially as first-line therapy for degenerative mitral regurgitation patients, including both surgery-eligible and surgery-ineligible populations.

Product and service1 record
1CardioMech MVRS (Mitral Valve Repair System)
CategoryStructural Heart Medical Devices
Description

A transcatheter mitral valve repair system that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart under echocardiographic guidance. Designed for simple, potentially sub-hour procedures in simple DMR cases with capability to deploy up to two chords in complex cases, intended as a less-invasive alternative to open-heart surgery and a candidate first-line therapy for degenerative mitral regurgitation. For investigational use only.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Anteris Technologies is developing the DurAVR THV system for transcatheter aortic valve replacement and is expanding into structural heart. As a small-cap structural heart device developer with overlapping R&D and commercialization challenges, it is comparable in stage and category focus to CardioMech.

TypeDirect peer
Description

NeoChord develops the NeoChord DS1000 system for transapical, beating-heart artificial chord implantation to treat degenerative mitral regurgitation. It is the closest direct competitor to CardioMech MVRS, also using artificial chordal replacement, though with a transapical rather than transfemoral transseptal delivery approach.

TypeBroad incumbent
Description

Edwards Lifesciences is a dominant structural heart incumbent with the PASCAL transcatheter mitral repair system and the TAVR franchise (Sapien). Directly competes with CardioMech in transcatheter mitral valve repair and acquired Harpoon Medical (another chordal repair player), making it both a competitor and likely strategic acquirer.

TypeBroad incumbent
Description

Medtronic acquired CathWorks (former employer of CardioMech Chairman Mousavi) for $585M and competes broadly in structural heart with Intrepid TMVR, the Harmony TPV, and its TAVR franchise. It is both a direct competitor in transcatheter mitral and a likely strategic acquirer of novel chordal repair platforms.

TypeEmerging player
Description

Cardiac Dimensions markets the Carillon System for transcatheter mitral annuloplasty to treat functional mitral regurgitation. It addresses the same mitral regurgitation patient population as CardioMech, albeit with a different anatomic mechanism (annuloplasty vs. chordal replacement).

6Polares Medical
TypeEmerging player
Description

Polares Medical is developing a transcatheter mitral valve replacement system targeting both functional and degenerative mitral regurgitation. As an emerging transcatheter mitral player, it competes for the same clinical and strategic attention as CardioMech within structural heart programs and investment flows.

TypeBroad incumbent
Description

Boston Scientific operates in structural heart and acquired Farapulse and Apollo Endosurgery as part of its growth strategy. While its mitral valve portfolio is more limited, it remains a broad incumbent with the resources and clinical infrastructure to compete with or acquire transcatheter mitral players like CardioMech.

TypeEmerging player
Description

CroíValve is developing a transcatheter tricuspid and mitral coaptation device for patients with severe regurgitation. It is an emerging structural heart player addressing overlapping patient populations and competing for similar venture and strategic capital as CardioMech.

9Abbott
TypeBroad incumbent
Description

Abbott markets the MitraClip, the most widely adopted transcatheter edge-to-edge mitral repair device, and the TriClip tricuspid system. It competes directly with CardioMech's transcatheter mitral approach and possesses the scale, sales force, and clinical evidence to defend share in structural heart.

TypeEmerging player
Description

4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR). As an emerging structural heart company focused on mitral disease, it competes for the same patient population as CardioMech MVRS, though via replacement rather than repair.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CardioMech

Structural Heart Medical Devicescardiomech.com

CardioMech is a Norwegian medical device company developing the CardioMech MVRS, a transcatheter mitral valve repair system using artificial chordal replacement to treat degenerative mitral regurgitation as a less-invasive alternative to open-heart surgery. It targets interventional cardiologists, cardiac surgeons, and DMR patients in Europe and the United States.

What CardioMech does

CardioMech AS is a privately held Norwegian medical device company developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter platform designed to treat degenerative mitral regurgitation (DMR) without open-heart surgery. The system deploys artificial chord(s) through a transfemoral, transseptal catheter to replace broken or elongated native chordae tendineae, restoring native valve anatomy on a beating heart under echocardiographic guidance. Procedures are designed to be simple and potentially sub-hour for straightforward cases, with the ability to deploy up to two chords for more complex anatomy, and the small implant size is intended to preserve future surgical or transcatheter therapy options. The device is positioned as a potential first-line transcatheter therapy for both surgery-eligible and surgery-ineligible DMR patients, targeting the same disease space as the $6B-plus TAVR market but for the mitral valve.

The company is headquartered in Trondheim, Norway, with US operations in Fridley, Minnesota to support clinical trials and regulatory engagement in the US market. CardioMech MVRS is investigational only and not approved for sale in any geography; an Early Feasibility Study is registered on clinicaltrials.gov. Leadership includes co-founders Jacob Bergsland (CMO) and Nikolai Hiorth (CTO), CEO/President Rick Nehm, and Chairman Ramin Mousavi, the former CEO of CathWorks (acquired by Medtronic for $585M in April 2026), who brings Edwards Lifesciences and Baxter experience.

The business model is a future medical-device hardware-sale model: revenue will ultimately be generated through sale of the artificial-chord implant and delivery system to hospitals and cardiac centers performing transcatheter mitral valve repair, supplemented by clinical training and support services. Pricing is not publicly disclosed because no commercial sales exist today. The company has raised approximately $84M cumulatively across eight disclosed rounds between 2019 and April 2025, with recent rounds led or backed by Hadean Ventures, Investinor, Aerion Partners, and an undisclosed strategic investor; all US capital raises have been registered via SEC Form D filings.

CardioMech firmographics

Firmographics
Name
CardioMech
Legal name
CardioMech AS
Website
https://cardiomech.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
CardioMech is a Norwegian medical device company developing the CardioMech MVRS, a transcatheter mitral valve repair system using artificial chordal replacement to treat degenerative mitral regurgitation as a less-invasive alternative to open-heart surgery. It targets interventional cardiologists, cardiac surgeons, and DMR patients in Europe and the United States.
Ownership category
akta.pro rank

CardioMech industry classification

Industry
Product category
Structural Heart Medical Devices
NAICS
Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Structural heart devices
  • Mitral valve repair
  • Transcatheter cardiac devices
  • Artificial chord implants
  • Degenerative mitral regurgitation therapy

Where CardioMech is headquartered

Location

Headquarters

HQ city
Trondheim
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

CardioMech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: As a medical device company developing an implantable device for transcatheter mitral valve repair, CardioMech will generate revenue through the sale of its artificial chord implants and associated delivery systems to hospitals and cardiac centers performing the procedures.
  2. Clinical Training and Support: Potential revenue from training, support, and clinical consultation services for hospitals and cardiac centers adopting the CardioMech MVRS platform.

Go-to-market motion2 records

CardioMech product offering

Product offering

Core offering

CardioMech is developing the CardioMech MVRS, a transcatheter mitral valve repair platform that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart. The system is intended as a less-invasive alternative to open-heart surgery for patients with degenerative mitral regurgitation, including those considered surgically ineligible. The device is for investigational use only and is not yet available for sale.

Product overview

CardioMech is developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter mitral valve repair platform. The system uses artificial chords designed to reduce or eliminate mitral regurgitation and restore native anatomy. It is a catheter-based therapy intended as an alternative to open-heart surgery and potentially as first-line therapy for degenerative mitral regurgitation patients, including both surgery-eligible and surgery-ineligible populations.

Differentiator

Problem solved

Functional benefit

Products and services

  • CardioMech MVRS (Mitral Valve Repair System) A transcatheter mitral valve repair system that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart under echocardiographic guidance. Designed for simple, potentially sub-hour procedures in simple DMR cases with capability to deploy up to two chords in complex cases, intended as a less-invasive alternative to open-heart surgery and a candidate first-line therapy for degenerative mitral regurgitation. For investigational use only.

Quantifiable outcome

  • Potential to reduce the need for open-heart surgery in degenerative mitral regurgitation patients
  • +2 more outcomes

Companies that use CardioMech

Customer profile

Segments2 records

Ideal customer profiles1 record

CardioMech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

CardioMech partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

CardioMech competitors and assessment

Company assessment

Emerging players

  • Anteris Technologies: Anteris Technologies is developing the DurAVR THV system for transcatheter aortic valve replacement and is expanding into structural heart. As a small-cap structural heart device developer with overlapping R&D and commercialization challenges, it is comparable in stage and category focus to CardioMech.
  • Cardiac Dimensions: Cardiac Dimensions markets the Carillon System for transcatheter mitral annuloplasty to treat functional mitral regurgitation. It addresses the same mitral regurgitation patient population as CardioMech, albeit with a different anatomic mechanism (annuloplasty vs. chordal replacement).
  • Polares Medical: Polares Medical is developing a transcatheter mitral valve replacement system targeting both functional and degenerative mitral regurgitation. As an emerging transcatheter mitral player, it competes for the same clinical and strategic attention as CardioMech within structural heart programs and investment flows.
  • CroíValve: CroíValve is developing a transcatheter tricuspid and mitral coaptation device for patients with severe regurgitation. It is an emerging structural heart player addressing overlapping patient populations and competing for similar venture and strategic capital as CardioMech.
  • 4C Medical Technologies: 4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR). As an emerging structural heart company focused on mitral disease, it competes for the same patient population as CardioMech MVRS, though via replacement rather than repair.

Direct peers

  • NeoChord: NeoChord develops the NeoChord DS1000 system for transapical, beating-heart artificial chord implantation to treat degenerative mitral regurgitation. It is the closest direct competitor to CardioMech MVRS, also using artificial chordal replacement, though with a transapical rather than transfemoral transseptal delivery approach.

Broad incumbents

  • Edwards Lifesciences: Edwards Lifesciences is a dominant structural heart incumbent with the PASCAL transcatheter mitral repair system and the TAVR franchise (Sapien). Directly competes with CardioMech in transcatheter mitral valve repair and acquired Harpoon Medical (another chordal repair player), making it both a competitor and likely strategic acquirer.
  • Medtronic: Medtronic acquired CathWorks (former employer of CardioMech Chairman Mousavi) for $585M and competes broadly in structural heart with Intrepid TMVR, the Harmony TPV, and its TAVR franchise. It is both a direct competitor in transcatheter mitral and a likely strategic acquirer of novel chordal repair platforms.
  • Boston Scientific: Boston Scientific operates in structural heart and acquired Farapulse and Apollo Endosurgery as part of its growth strategy. While its mitral valve portfolio is more limited, it remains a broad incumbent with the resources and clinical infrastructure to compete with or acquire transcatheter mitral players like CardioMech.
  • Abbott: Abbott markets the MitraClip, the most widely adopted transcatheter edge-to-edge mitral repair device, and the TriClip tricuspid system. It competes directly with CardioMech's transcatheter mitral approach and possesses the scale, sales force, and clinical evidence to defend share in structural heart.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CardioMech social profiles

Digital presence

CardioMech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CardioMech leadership team

Management profile

Number of profiles

Profiles4 records

CardioMech funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CardioMech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioMech

What does CardioMech do?

CardioMech is developing the CardioMech MVRS, a transcatheter mitral valve repair platform that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart. The system is intended as a less-invasive alternative to open-heart surgery for patients with degenerative mitral regurgitation, including those considered surgically ineligible. The device is for investigational use only and is not yet available for sale.

Is CardioMech a public or private company?

CardioMech is a private company. It is classified as venture growth investor backed and is currently operating.

When was CardioMech founded?

CardioMech was founded in 2018. It employs 1 to 10 people.

Where is CardioMech based?

CardioMech is headquartered in Trondheim, Norway, in the Europe region.

How does CardioMech make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Training and Support.

Who are CardioMech's main competitors?

Emerging players on record are Anteris Technologies, Cardiac Dimensions, Polares Medical, CroíValve and 4C Medical Technologies. NeoChord is listed as a direct peer. Broad incumbents are Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.

Does CardioMech have an API?

No public API is recorded for CardioMech.

What industry is CardioMech in?

CardioMech's product category is Structural Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device and Diagnostic industryCardioMech Obtains Funds for Future New Mitral Valve Repair TrialCardioMech secured $18.5 million in Series A financing to fund its first-in-human feasibility trial for a new percutaneous mitral valve repair device. The company plans to submit an Investigational Device Exemption (IDE) to the FDA, with the study expected to involve up to 15 patients across five centers in the United States. This development marks a key step toward evaluating the technology's ability to treat patients who are high-risk candidates for traditional open-heart surgery.MassDeviceFormer CathWorks CEO Ramin Mousavi to chair board of mitral valve repair company CardioMechCardioMech, a Norway-based mitral valve repair company with U.S. operations in Minnesota, appointed Ramin Mousavi as chair of its board of directors. Mousavi previously served as president, CEO and board member of CathWorks, which was acquired by Medtronic for $585 million earlier this year, and held senior leadership roles at Baxter and Edwards Lifesciences. The appointment brings experience in transcatheter heart valve development and AI-derived coronary physiology to guide CardioMech's chordal repair platform toward potential first-line therapy status for degenerative mitral regurgitation patients.OcbjRamin Mousavi Appointed Chairman of CardioMechRamin Mousavi, CEO of CathWorks, has been appointed as board chair of Norway-based medical device company CardioMech AS, which is developing a catheter-based repair system for degenerative mitral regurgitation. The appointment adds leadership experience to CardioMech as it advances its structural heart technology toward potential commercialization. Background context notes that CathWorks, Mousavi's employer, was acquired by Medtronic for $585 million in April following a co-promotion agreement.PR NewswireCardioMech Shareholders Appoint Ramin Mousavi as Chairman of the BoardNorway-based medical device company CardioMech AS has appointed Ramin Mousavi, a veteran medtech executive with experience at Edwards Lifesciences, Baxter International, and as former CEO of CathWorks (acquired by Medtronic in April 2026), as Chairman of the Board effective immediately. Mousavi brings expertise in transcatheter heart valve technology and will work with the leadership team to advance CardioMech's investigational transcatheter mitral valve repair platform for treating degenerative mitral regurgitation. The company, headquartered in Fridley, Minnesota, positions the technology as potentially disruptive to the standard of care for the millions of patients suffering from this condition.BioSpaceCardioMech Shareholders Appoint Ramin Mousavi as Chairman of the BoardCardioMech AS appointed Ramin Mousavi as chairman of the board, effective immediately. Mousavi previously led CathWorks, acquired by Medtronic in April 2026, and held senior roles at Baxter and Edwards. He will work with the board to advance the company's mitral valve repair technology.BioSpaceCardioMech Shareholders Appoint Ramin Mousavi as Chairman of the BoardCardioMech AS appointed Ramin Mousavi as chairman of the board, effective immediately. Mousavi previously led CathWorks, acquired by Medtronic in April 2026, and held senior roles at Baxter and Edwards. He will work with the board to advance CardioMech's mitral valve repair technology.PR NewswireCARDIOMECH RAISES $13M IN HEAVILY OVERSUBSCRIBED ROUND FOR ITS TRANSCATHETER MITRAL CHORDAL REPAIR TECHNOLOGYNorway-based medical device company CardioMech AS has closed a $13 million funding round for its transcatheter mitral chordal repair technology, bringing total capital raised to $42 million. The heavily oversubscribed investment reflects strong investor confidence in the device as a potential first-line therapy for degenerative mitral regurgitation. This development supports the company's efforts to provide a less-invasive alternative to open-heart surgery for patients eligible or ineligible for traditional procedures.FinSMEsCardioMech Raises $13M in FundingCardioMech AS, a medical device company based in Trondheim, Norway, raised $13 million in funding, bringing its total capitalization to $42 million. The company plans to utilize these funds to expand its operations and research and development efforts for its transcatheter mitral valve chordal repair technology.BioSpaceCardioMech Raises $13m in Heavily Oversubscribed Round for Its Transcatheter Mitral Chordal Repair TechnologyNorway-based medical device company CardioMech AS announced the closing of a $13 million funding round, bringing its total capital raised to $42 million. The heavily oversubscribed round includes support from existing and new investors, reflecting confidence in the company's transcatheter mitral chordal repair technology as a potential first-line therapy for degenerative mitral regurgitation.